These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30249040)

  • 1. Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
    Sayour EJ; Mendez-Gomez HR; Mitchell DA
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.
    Varypataki EM; Silva AL; Barnier-Quer C; Collin N; Ossendorp F; Jiskoot W
    J Control Release; 2016 Mar; 226():98-106. PubMed ID: 26876760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Delivery for Cancer Immunotherapy and Vaccines.
    Batty CJ; Tiet P; Bachelder EM; Ainslie KM
    Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-based immunity-inducing systems for cancer immunotherapy.
    Yuba E
    Mol Immunol; 2018 Jun; 98():8-12. PubMed ID: 29128232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-sensitive polymer-modified liposome-based immunity-inducing system: Effects of inclusion of cationic lipid and CpG-DNA.
    Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
    Biomaterials; 2017 Oct; 141():272-283. PubMed ID: 28704679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Components, Formulations, Deliveries, and Combinations of Tumor Vaccines.
    Liu T; Yao W; Sun W; Yuan Y; Liu C; Liu X; Wang X; Jiang H
    ACS Nano; 2024 Jul; 18(29):18801-18833. PubMed ID: 38979917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
    Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
    Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VLPs and particle strategies for cancer vaccines.
    Ungaro F; Conte C; Quaglia F; Tornesello ML; Buonaguro FM; Buonaguro L
    Expert Rev Vaccines; 2013 Oct; 12(10):1173-93. PubMed ID: 24124878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines to treat cancer--an old approach whose time has arrived.
    Hellstrom KE; Hellstrom I
    J Cell Biochem; 2007 Oct; 102(2):291-300. PubMed ID: 17729239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes composed of reconstituted membranes for induction of tumor-specific immunity.
    Westerman LE; Jensen PE
    Methods Enzymol; 2003; 373():118-27. PubMed ID: 14714400
    [No Abstract]   [Full Text] [Related]  

  • 14. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
    Grabbe S; Haas H; Diken M; Kranz LM; Langguth P; Sahin U
    Nanomedicine (Lond); 2016 Oct; 11(20):2723-2734. PubMed ID: 27700619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy.
    Yuba E; Kanda Y; Yoshizaki Y; Teranishi R; Harada A; Sugiura K; Izawa T; Yamate J; Sakaguchi N; Koiwai K; Kono K
    Biomaterials; 2015 Oct; 67():214-24. PubMed ID: 26222284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory colloidal delivery systems for cancer vaccines.
    Saupe A; McBurney W; Rades T; Hook S
    Expert Opin Drug Deliv; 2006 May; 3(3):345-54. PubMed ID: 16640495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
    J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy.
    Miyabe H; Hyodo M; Nakamura T; Sato Y; Hayakawa Y; Harashima H
    J Control Release; 2014 Jun; 184():20-7. PubMed ID: 24727060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
    Kobiyama K; Ishii KJ
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.